Cytokines and bone loss in a 5-year longitudinal study - Hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: The Danish Osteoporosis Prevention Study
Cytokines and bone loss in a 5-year longitudinal study - Hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: The Danish Osteoporosis Prevention Study
复制标题
DOI：
10.1359/jbmr.2000.15.8.1545
复制
发表时间：
2000-08-01
影响因子：
6.2
通讯作者：
Beck-Nielsen, H
中科院分区：
文献类型：
--
作者：
Abrahamsen, B;Bonnevie-Nielsen, V;Beck-Nielsen, H
促炎细胞因子白细胞介素-1 β IL-1 β和IL-6可能在加速绝经后骨质流失中发挥核心作用，但观察性研究导致了相互矛盾的结果，IL-1受体拮抗剂（IL-1 ra）和可溶性IL-6受体（sIL-6 R）产生的雌激素依赖性变化可能改变细胞因子生物活性，因此，我们在一项为期5年的纵向研究中评估了绝经和激素替代治疗（HRT）对血清中细胞因子和活性调节剂的影响。160名围绝经期妇女（年龄50.1 ± 2.8岁）随机接受HRT或不接受治疗。血清IL-6随年龄增长而增加（r = 0.16; p < 0.05），但细胞因子与基线骨密度（BMD）无关。HRT导致IL-1 ra（p < 0.001）和IL-6（p < 0.05）的小幅升高，sIL-6 R降低（p < 0.01），而IL-1 β无变化。IL-1 ra与前臂超远端的骨丢失呈负相关（r = 0.29;p < 0.05），与脊柱的骨丢失呈较小程度的负相关（r = 0.20; p = 0.09）。此外，sIL-6 R与前臂超远端骨丢失呈弱正相关（r = 0.26;p < 0.05）。高IL-6水平与较慢的骨丢失相关（脊柱r = 0.31，p < 0.01），并且控制年龄并没有减弱这种关联。HRT期间sIL-6 R的百分比变化与股骨颈的骨丢失相关（r = -0.29; p < 0.01），与脊柱的骨丢失弱相关（r = -0.16;p = 0.17）。总之，血清IL-1 ra和sIL-6 R受HRT的影响，并与围绝经期妇女的骨丢失率有关。
The proinflammatory cytokines interleukin-1 beta (IL-1 beta) and IL-6 may play a central role in the acceleration of postmenopausal bone loss, but observational studies have led to contradictory results, Estrogen-dependent changes in the production of IL-1 receptor antagonist (IL-1ra) and the soluble IL-6 receptor (sIL-6R) potentially modify cytokine bioactivity, We therefore assessed the impact of menopause and hormone replacement therapy (HRT) on cytokines and activity modifiers in serum within a 5-year longitudinal study. One hundred sixty perimenopausal women (age 50.1 +/- 2.8 years) were randomized to HRT or no treatment. Serum IL-6 increased with age (r = 0.16; p < 0.05), but cytokines did not correlate with baseline bone mineral density (BMD). HRT led to small increases in IL-1ra (p < 0.001) and IL-6 (p < 0.05), with a decrease in sIL-6R (p < 0.01) and no change in IL-1 beta, No changes were observed in the control group. IL-1ra was inversely correlated with bone loss at the ultradistal forearm (r = 0.29;p < 0.05) and to a lesser degree at the spine (r = 0.20; p = 0.09). In addition, there was a weak positive correlation between sIL-6R and bone loss at the ultradistal forearm (r = 0.26;p < 0.05). High IL-6 levels were associated with slower bone loss (spine r = 0.31, p < 0.01) and controlling for age did not diminish this association, The percent change in sIL-6R during HRT was correlated with the bone loss at the femoral neck (r = -0.29; p < 0.01) and weakly with bone loss in the spine (r = -0.16;p = 0.17). In conclusion, serum IL-1ra and sIL-6R are influenced by HRT and are associated with the rate of bone loss in perimenopausal women.